IB
AXSM icon

Intrust Bank’s Axsome Therapeutics AXSM Stock Holding History

Intrust Bank’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
4,779
+271
+6% +$58.8K 0.09% 151
2026
Q1 		$762K Buy
4,508
+456
+11% +$78.8K 0.06% 210
2025
Q4 		$740K Buy
4,052
+288
+8% +$40.2K 0.06% 200
2025
Q3 		$457K Buy
3,764
+889
+31% +$100K 0.04% 271
2025
Q2 		$300K Sell
2,875
-218
-7% -$23.1K 0.03% 343
2025
Q1 		$361K Buy
3,093
+270
+10% +$30.8K 0.04% 295
2024
Q4 		$239K Buy
2,823
+183
+7% +$16.8K 0.02% 355
2024
Q3 		$237K Sell
2,640
-42
-2% -$3.67K 0.02% 362
2024
Q2 		$216K Sell
2,682
-258
-9% -$19.1K 0.02% 363
2024
Q1 		$235K Buy
2,940
+94
+3% +$7.89K 0.03% 364
2023
Q4 		$227K Sell
2,846
-350
-11% -$23.4K 0.03% 359
2023
Q3 		$223K Buy
3,196
+150
+5% +$11.2K 0.03% 346
2023
Q2 		$219K Buy
+3,046
New +$225K 0.03% 365
2023
Q1 		– Sell
-3,460
Closed -$267K – 394
2022
Q4 		$267K Buy
+3,460
New +$207K 0.04% 332

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Intrust Bank's AXSM Position: Q2 2026 in Review

Intrust Bank increased its Axsome Therapeutics (AXSM) stake by 6% in Q2 2026, buying an estimated $58.8K and bringing the position to 4,779 shares worth $1.17M. The position accounts for 0.09% of the portfolio, ranked #151.

Intrust Bank first reported a position in AXSM in Q4 2022 and has held it in 14 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Intrust Bank held 4,779 shares of Axsome Therapeutics worth $1.17M as of Q2 2026.
  • Intrust Bank bought 271 Axsome Therapeutics shares in Q2 2026, an estimated $58.8K.
  • Axsome Therapeutics made up 0.09% of Intrust Bank's portfolio in Q2 2026, its #151 holding.
  • Intrust Bank first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Intrust Bank's 13F filing for Q2 2026, filed 5 Aug 2026.